20-21 October

Chairs – Ahmed Bennis and Frieder Braunschweig
• ESC Guidelines update – Marco Metra
• New consensus on HF management of Australian clinicians – Alicia Chan
• Acute heart failure and valvular heart disease: a scientific statement of the Heart Failure Association – Ovidiu Chioncel
• Patient phenotyping in HFpEF – Stefan Anker

Chairs – Michael Böhm and Frieder Braunschweig
• Foundational therapies in HFrEF – John McMurray
• Individualising GDMT implementation – Gianluigi Savarese
• Learnings from STRONG HF – Marianna Adamo

Chairs – Stefan Anker and Clara Ines Saldarriaga
• SGLT2 inhibition in 2023: what’s exciting? – Milton Packer
• Early initiation to achieve rapid clinical benefits – Shelley Zieroth
• What about HF with improved ejection fraction? – Muthiah Vaduganathan
• Sotaglifozin: what’s new? – Deepak Bhatt

Chairs – Mikhail Kosiborod and Stefan Anker
• Obesity and heart failure: epidemiology and mechanisms – Massimo Piepoli
• Weight gain / weight loss in HF – Giulia Ferranini
• The obesity paradox – Wolfram Doehner
• Overview of current therapeutic agents – Mark Petrie

Chairs – Gerasimos Filippatos and Ileana Pina
• HFA clinical statement on worsening HF – Marianna Adamo
• SGLT2s in patients hospitalised for acute HF – Piotr Ponikowski
• Vericiguat: the 5th pillar? – Javed Butler
• Omecamtiv Mecarbil: what’s next? – John Teerlink

Chairs – Piotr Ponikowski and Yuhui Zhang
• Iron deficiency and cardiovascular processes: what have we learnt so far? – Ewa Jankowska
• Latest data on ferric derisomaltose – John Cleland
• IV iron in HF: insights from recent meta analysis – Piotr Ponikowski
• What about dose? – Stephan von Haehling

Chairs – Harriette van Spall and Brenda Moura
• Which comorbidities matter most?
• New MRAs for the management of patients with T2D and CKD – Gerasimos Filippatos
• Focus on hypertension – Michael Böhm
• Managing hyperkalemia – Joao Ferreira

Chairs – Javed Butler and Giuseppe Rosano
• CRT: a cornerstone of HF care
• Neuromodulation therapy for HFrEF – Javier de Juan Bagudá
• CCM: benefits of early implementation – Marat Fudim
• Interatrial shunts – William Abraham

Chairs – William Abraham and John Cleland
• Telemonitoring for heart failure – Lynne Stevenson
• MONITOR HF: what do we learn about haemodynamic monitoring? – Jasper Brugts
• Lung fluid remote management
• Highlights of innovation and technologies in HF – Daniel Burkhoff

Chairs – Maria Cecilia Bahit and Horst Sievert
• Targeting FMR in HF – Klaus Witte
• Managing TR HF – Paul Sorajja
• Amyloid cardiomyopathy HF
• Secondary pulmonary hypertension in HF – Stephan Rosenkranz